PreveCeutical Medical Inc. (PRVCF)
USD 0.02
(6.4%)
USD 0.02
(6.4%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 963.12 Thousand CAD | -11.46% |
| 2022 | 1.08 Million CAD | 21.15% |
| 2021 | 897.85 Thousand CAD | -58.49% |
| 2020 | 2.16 Million CAD | -38.36% |
| 2019 | 3.5 Million CAD | -49.41% |
| 2018 | 6.93 Million CAD | 53.91% |
| 2017 | 4.5 Million CAD | 66.79% |
| 2016 | 2.7 Million CAD | 4227.59% |
| 2015 | 62.45 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 139.61 Thousand CAD | -60.14% |
| 2024 Q2 | 273.02 Thousand CAD | 97.37% |
| 2023 Q2 | 160.07 Thousand CAD | -45.23% |
| 2023 Q3 | 153.12 Thousand CAD | -4.35% |
| 2023 Q1 | 292.25 Thousand CAD | 12.06% |
| 2023 Q4 | 350.24 Thousand CAD | 128.74% |
| 2023 FY | 953.26 Thousand CAD | -12.36% |
| 2022 Q1 | 161.06 Thousand CAD | -44.34% |
| 2022 FY | 1.08 Million CAD | 21.15% |
| 2022 Q4 | 260.8 Thousand CAD | -47.35% |
| 2022 Q3 | 495.4 Thousand CAD | 185.06% |
| 2022 Q2 | 173.78 Thousand CAD | 7.9% |
| 2021 Q1 | 377.37 Thousand CAD | -75.48% |
| 2021 Q4 | 289.36 Thousand CAD | 431.83% |
| 2021 Q3 | -87.2 Thousand CAD | -127.4% |
| 2021 Q2 | 318.31 Thousand CAD | -15.65% |
| 2021 FY | 897.85 Thousand CAD | -58.49% |
| 2020 Q1 | 279.75 Thousand CAD | 55.35% |
| 2020 Q3 | -420.82 Thousand CAD | -156.19% |
| 2020 Q4 | 1.53 Million CAD | 465.72% |
| 2020 FY | 2.16 Million CAD | -38.36% |
| 2020 Q2 | 748.91 Thousand CAD | 167.7% |
| 2019 Q2 | 1.36 Million CAD | 29.17% |
| 2019 Q4 | 180.08 Thousand CAD | -80.05% |
| 2019 Q3 | 902.7 Thousand CAD | -34.01% |
| 2019 FY | 3.5 Million CAD | -49.41% |
| 2019 Q1 | 1.05 Million CAD | 2.21% |
| 2018 Q1 | 1.34 Million CAD | -42.75% |
| 2018 FY | 6.93 Million CAD | 53.91% |
| 2018 Q2 | 2.09 Million CAD | 56.29% |
| 2018 Q3 | 2.49 Million CAD | 19.12% |
| 2018 Q4 | 1.03 Million CAD | -58.5% |
| 2017 Q3 | 1.13 Million CAD | 68.33% |
| 2017 FY | 4.5 Million CAD | 66.79% |
| 2017 Q1 | 94.55 Thousand CAD | -20.86% |
| 2017 Q2 | 672.67 Thousand CAD | 611.4% |
| 2017 Q4 | 2.34 Million CAD | 106.89% |
| 2016 Q3 | 106.02 Thousand CAD | 297.5% |
| 2016 FY | 2.7 Million CAD | 4227.59% |
| 2016 Q1 | 32.29 Thousand CAD | 90.42% |
| 2016 Q4 | 119.47 Thousand CAD | 12.69% |
| 2016 Q2 | 26.67 Thousand CAD | -17.41% |
| 2015 FY | 62.45 Thousand CAD | 0.0% |
| 2015 Q3 | 1704.00 CAD | 0.0% |
| 2015 Q4 | 16.96 Thousand CAD | 895.36% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 3.65 Million USD | 73.618% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 28.208% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 63.345% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 96.741% |
| GB Sciences, Inc. | 1.42 Million USD | 32.199% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 71.714% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -337.628% |
| Skye Bioscience, Inc. | 13.54 Million USD | 92.891% |
| Zenith Capital Corp. | 8.94 Million USD | 89.23% |
| Agentix Corp. | 1.37 Million USD | 29.789% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 80.898% |
| Biomind Labs Inc. | 994.18 Thousand USD | 3.124% |
| ContraFect Corporation | 56.88 Million USD | 98.307% |
| CSL Limited | 3.44 Billion USD | 99.972% |
| CytoDyn Inc. | 18.05 Million USD | 94.666% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 48.341% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -147.23% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 98.323% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -131.811% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 35.873% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -4.29% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 97.415% |
| SQZ Biotechnologies Company | 85.61 Million USD | 98.875% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 52.989% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 98.89% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 66.974% |
| Mesoblast Limited | 5.9 Million USD | 83.681% |
| Marizyme, Inc. | 19.23 Million USD | 94.994% |
| Genus plc | 147.7 Million USD | 99.348% |
| Pharming Group N.V. | 225.49 Million USD | 99.573% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 88.45% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 34.869% |
| IMV Inc. | 37.7 Million USD | 97.446% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 65.484% |
| MultiCell Technologies, Inc. | 567.42 USD | -169637.408% |
| ONE Bio Corp. | 6.44 Million USD | 85.054% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 98.879% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 96.103% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 45.267% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 85.664% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 3952.496% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 93.984% |
| Alpha Cognition Inc. | 9.7 Million USD | 90.077% |
| Enzolytics Inc. | 2.17 Million USD | 55.81% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.937% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 7.747% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 59.952% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.883% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 80.416% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -267.989% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 60.774% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -461.559% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 49.861% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 89.03% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 78.154% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 3.74 Million USD | 74.292% |
| Helix BioMedix, Inc. | 1.97 Million USD | 51.161% |
| EV Biologics, Inc. | 531.96 Thousand USD | -81.051% |
| Q BioMed Inc. | 3.43 Million USD | 71.975% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 91.137% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.03% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | 95.808% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 47.516% |
| HST Global, Inc. | 140.9 Thousand USD | -583.517% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | 27.879% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 14.382% |
| Halberd Corporation | 74.84 Thousand USD | -1186.876% |
| Resverlogix Corp. | 12.71 Million USD | 92.424% |
| Cell Source, Inc. | 4.32 Million USD | 77.733% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 39.018% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.31 Million USD | 86.825% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -5428.523% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.46 Million USD | 60.956% |
| Kadimastem Ltd | 2.41 Million USD | 60.038% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 77.276% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -430.691% |
| LadRx Corporation | 3.81 Million USD | 74.733% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -4.29% |
| Affymax, Inc. | 39.38 Million USD | 97.555% |
| Itoco Inc. | 919.14 Thousand USD | -4.785% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 13.93% |
| Mobile Lads Corp. | 554.54 Thousand USD | -73.678% |
| International Stem Cell Corporation | 5.27 Million USD | 81.728% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 3.82 Million USD | 74.788% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -3726.628% |
| Qrons Inc. | 643.67 Thousand USD | -49.628% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 32.164% |
| SYBLEU INC | 160.87 Thousand USD | -498.675% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | 56.808% |
| Rebus Holdings, Inc. | 664 Thousand USD | -45.049% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 46.974% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -1729.573% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -4634.425% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 97.344% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 40.474% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -30.889% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 69.041% |
| Neutra Corp. | 243.82 Thousand USD | -295.013% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 94.483% |
| PureTech Health plc | 144.59 Million USD | 99.334% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 95.3% |
| IXICO plc | 4.7 Million USD | 79.538% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 89.052% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.182% |
| CSL Limited | 3.89 Billion USD | 99.975% |
| Cellectis S.A. | 97.32 Million USD | 99.01% |